Please assess the completion status of the following clinical trial:

Trial Title: Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older.~2. Ocular hypertension or open-angle glaucoma in both eyes.~3. Unmedicated intraocular pressure \> 17 mmHg in one or both eyes and \< 30 mmHg in both eyes.~4. Corrected visual acuity in each eye equivalent to 20/200 or better.~5. Able and willing to give signed informed consent and follow study instructions.~Exclusion Criteria:~1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.~2. Intraocular pressure ≥ 30 mmHg.~3. Use of ocular medications within 30 days.~4. Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.~5. Previous eye surgery (other than cataract).~6. Ocular trauma within 6 months.~7. Clinically significant ocular disease that might interfere with the study.~8. Central corneal thickness greater than 620 µm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): 1 drop in each eye (OU) daily
- Netarsudil Ophthalmic Solution Vehicle (Type: PLACEBO_COMPARATOR): 1 drop in each eye (OU) daily

Based on this trial design, predict the completion outcome and termination type (if applicable).